#1 Clinical Trials Search in Europe

Certolizumab Pegol

This article examines the use of Certolizumab Pegol (CZP) in clinical trials for various conditions including Crohn’s disease, plaque psoriasis, rheumatoid arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis. CZP is a biologic medication that works by reducing inflammation in the body. The trials assess its efficacy, safety, and optimal dosing regimens in different patient populations.

Table of Contents

What is Certolizumab Pegol?

Certolizumab Pegol, also known by its brand name Cimzia, is a medication used to treat various inflammatory conditions[1]. It belongs to a class of drugs called tumor necrosis factor (TNF) inhibitors, which work by reducing inflammation in the body[1]. Other names for this medication include CDP870 and CZP[2].

What Conditions Does Certolizumab Pegol Treat?

Certolizumab Pegol is used to treat several inflammatory conditions, including:

  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting the joints[1]
  • Crohn’s Disease: An inflammatory bowel disease that affects the digestive tract[3]
  • Axial Spondyloarthritis (axSpA): A type of arthritis that primarily affects the spine and sacroiliac joints[2]
  • Plaque Psoriasis: A skin condition characterized by red, scaly patches[4]
  • Polyarticular-course Juvenile Idiopathic Arthritis (JIA): A form of arthritis affecting children and adolescents[5]

How Does Certolizumab Pegol Work?

Certolizumab Pegol works by targeting and blocking a protein called tumor necrosis factor-alpha (TNF-alpha) in the body. TNF-alpha is responsible for promoting inflammation. By reducing the effects of this protein, Certolizumab Pegol helps to decrease inflammation and alleviate symptoms associated with various inflammatory conditions[3].

How is Certolizumab Pegol Administered?

Certolizumab Pegol is administered through subcutaneous (under the skin) injections. The dosage and frequency of administration may vary depending on the condition being treated and the patient’s weight. Generally, it is given as follows:

  • For adults: Usually 200 mg every two weeks or 400 mg every four weeks[1]
  • For children and adolescents: The dose is adjusted based on body weight[5]

The medication is typically provided in pre-filled syringes or auto-injection devices for ease of use[6].

How Effective is Certolizumab Pegol?

Clinical trials have shown Certolizumab Pegol to be effective in treating various inflammatory conditions:

  • In rheumatoid arthritis, many patients experience significant improvement in joint pain, swelling, and overall function[1]
  • For Crohn’s disease, it has shown effectiveness in reducing symptoms and promoting healing of intestinal lesions[3]
  • In axial spondyloarthritis, it helps reduce back pain and improve overall mobility[2]
  • For plaque psoriasis, it can lead to clearer skin and reduced symptoms[4]
  • In juvenile idiopathic arthritis, it helps reduce joint inflammation and improve daily functioning in children and adolescents[5]

The effectiveness is often measured using standardized scales such as the American College of Rheumatology (ACR) response criteria or the Psoriasis Area and Severity Index (PASI)[1][4].

What Are the Potential Side Effects?

Like all medications, Certolizumab Pegol can cause side effects. Common side effects may include:

  • Injection site reactions (redness, pain, or swelling at the injection site)
  • Upper respiratory tract infections
  • Headache
  • Rash

More serious side effects, although rare, can include:

  • Increased risk of serious infections
  • Allergic reactions
  • Nervous system problems
  • Blood problems

It’s important to discuss all potential risks and side effects with your healthcare provider[1][2].

Use in Special Populations

Certolizumab Pegol has been studied in various populations:

  • Children and Adolescents: It has been investigated for use in juvenile idiopathic arthritis, with dosing adjusted based on body weight[5]
  • Pregnant Women: While not explicitly mentioned in the provided trials, it’s important to note that the use of any medication during pregnancy should be discussed with a healthcare provider
  • Elderly Patients: The medication has been studied in adult populations, including older adults, but specific dosing adjustments for elderly patients were not mentioned in the provided information

As with any medication, the use of Certolizumab Pegol should be carefully considered and monitored by a healthcare professional, taking into account the individual patient’s condition, medical history, and potential risks and benefits[1][2].

Condition Study Population Key Outcomes Dosing Regimen
Crohn’s Disease Children and adolescents (ages 6-17) Clinical remission, PCDAI scores, growth parameters Weight-based dosing: 400mg or 200mg Q2W for induction, then 400mg or 200mg Q4W for maintenance
Plaque Psoriasis Adults with moderate to severe disease PASI 75/90 response, quality of life measures 400mg at Weeks 0, 2, 4, then 200mg Q2W
Rheumatoid Arthritis Adults with active disease ACR20/50/70 response, DAS28 scores, radiographic progression 200mg Q2W or 400mg Q4W
Axial Spondyloarthritis with Anterior Uveitis Adults with active disease and history of uveitis Reduction in uveitis flares, ASDAS scores, ASAS response 400mg at Weeks 0, 2, 4, then 200mg Q2W
Juvenile Idiopathic Arthritis Children and adolescents with polyarticular course PedACR30/50/70/90 response, safety and pharmacokinetics Weight-based dosing: 50-200mg Q2W or Q4W

FAQ

  • What conditions is Certolizumab Pegol being studied for in these clinical trials? Certolizumab Pegol is being studied for multiple conditions including Crohn's disease in children and adolescents, plaque psoriasis, rheumatoid arthritis, axial spondyloarthritis with anterior uveitis, and polyarticular-course juvenile idiopathic arthritis.
  • How is Certolizumab Pegol administered in these trials? Certolizumab Pegol is administered subcutaneously (under the skin) in these trials. The dosing regimens vary based on the condition and patient characteristics, but generally involve an initial loading dose followed by maintenance doses every 2 or 4 weeks.
  • What are some of the main outcomes being measured in these trials? The trials are measuring various outcomes including clinical remission rates, improvements in disease activity scores, reductions in symptoms like joint pain and swelling, changes in inflammatory markers, quality of life measures, and long-term safety outcomes like adverse events.
  • Are there any special considerations for pediatric patients in these trials? Yes, several trials are specifically focused on pediatric patients with conditions like Crohn's disease and juvenile idiopathic arthritis. These studies use weight-based dosing and assess outcomes using pediatric-specific measures like the Pediatric Crohn's Disease Activity Index (PCDAI) and Pediatric ACR response criteria.
  • What are some of the potential side effects being monitored in these trials? The trials are closely monitoring for adverse events, particularly serious adverse events and those leading to discontinuation of treatment. Specific side effects of interest include infections, injection site reactions, and the development of anti-drug antibodies.

Ongoing Clinical Trials on Certolizumab Pegol

  • Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Comparing certolizumab pegol and belimumab for patients with moderate or severe systemic lupus erythematosus

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Poland

  • Study on Certolizumab for Women with Unexplained Recurrent Implantation Failure

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Conventional Therapy and Biologic Treatments for Early Rheumatoid Arthritis Using Hydroxychloroquine, Abatacept, and Azathioprine in Responsive Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Iceland Norway Sweden

  • Study on Rheumatoid Arthritis: Evaluating Methotrexate, Golimumab, and Hydroxychloroquine Sulfate for Patients with Autoantibodies and Response to Glucocorticoids

    Not recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Nipocalimab and Certolizumab for Patients with Active Rheumatoid Arthritis After Advanced Therapy

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Poland

Glossary

  • Certolizumab Pegol (CZP): A biologic medication that reduces inflammation by blocking a protein called tumor necrosis factor (TNF). It is being studied for various autoimmune and inflammatory conditions.
  • Subcutaneous injection: A method of administering medication by injecting it into the fatty tissue just beneath the skin.
  • Loading dose: An initial higher dose of medication given at the start of treatment to quickly achieve an effective concentration in the body.
  • Maintenance dose: The regular dose of medication given after the loading dose to maintain therapeutic levels in the body.
  • Clinical remission: A state where the signs and symptoms of a disease are significantly reduced or absent.
  • Disease activity score: A measure used to assess the level of disease activity, often combining multiple clinical and laboratory parameters.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Anti-drug antibodies: Antibodies produced by the body against a therapeutic drug, which can potentially reduce its effectiveness.
  • Pediatric Crohn's Disease Activity Index (PCDAI): A tool used to measure disease activity in children with Crohn's disease, considering factors like symptoms, laboratory values, and growth.
  • American College of Rheumatology (ACR) response criteria: A set of measures used to assess improvement in rheumatoid arthritis and other rheumatic conditions, looking at factors like joint tenderness, swelling, and overall disease activity.

References

  1. https://clinicaltrials.gov/study/NCT00580840
  2. https://clinicaltrials.gov/study/NCT03020992
  3. https://clinicaltrials.gov/study/NCT01582568
  4. https://clinicaltrials.gov/study/NCT04053881
  5. https://clinicaltrials.gov/study/NCT01550003
  6. https://clinicaltrials.gov/study/NCT00845663